title: Cationic anticancer drugs and their modes of action.
abstract: This report focuses on two groups of cationic cancerostatics, anthracycline antibiotics and 1,4-benzoquinone-guanylhydrazone-thiosemicarbazone (ambazone), lining up biophysical and biochemical effects on the level of membranes and membrane constituents. The interaction of both drugs with multilamellar liposomes consisting of phosphatidylcholine used as a simple model membrane system could be ensured by means of steady state and nanosecond time-resolved fluorometric investigations. The biochemical effect on membranes is underlined by the inhibition of the neuraminidase activity of the Sendai virus, modification of the CAMP phosphodiesterase activity of leukemia L 1210 cells of mice and reduction of the lymphocyte blast transformation.
authors.affiliation: Academy of Sciences of the GDR, Central Institute of Microbiology and Experimental Therapy, Jena.
authors.forename: G
authors.initials: G
authors.lastname: Löber
authors.forename: K
authors.initials: K
authors.lastname: Geller
authors.forename: H
authors.initials: H
authors.lastname: Hanschmann
authors.forename: L M
authors.initials: LM
authors.lastname: Popa
authors.forename: R
authors.initials: R
authors.lastname: Repanovici
authors.forename: R
authors.initials: R
authors.lastname: Iliescu
authors.forename: W
authors.initials: W
authors.lastname: Römer
authors.forename: B
authors.initials: B
authors.lastname: Janke
authors.forename: V
authors.initials: V
authors.lastname: Kleinwächter
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000262:Adenylyl Cyclases / Q000378:metabolism; D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D003630:Daunorubicin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D005453:Fluorescence; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008935:Mitoguazone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D009439:Neuraminidase / Q000378:metabolism; D010222:Parainfluenza Virus 1, Human / Q000187:drug effects / Q000201:enzymology; D013053:Spectrophotometry
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; C010806:violamycins; D004317:Doxorubicin; D004247:DNA; C037931:1,4-benzoquinone guanylhydrazone thiosemicarbazone; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D009439:Neuraminidase; D000262:Adenylyl Cyclases; D008935:Mitoguazone; D003630:Daunorubicin